DDIT3 and diffuse large B-cell lymphoma: Although OBI (Gazyva) combined with CHOP (G-CHOP) was not superior over R-CHOP in clinical trials involving previously untreated DLBCL patients (NCT01659099, NCT01287741), some benefit of G-CHOP in terms of PFS was associated with GCB subtype of DLBCL [68,69].